Education
About Us
Working with TipRanks
Follow Us
Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
2395 Stock Chart & Stats
¥1622.00
¥20.00(1.21%)
At close: 4:00 PM EST
¥1622.00
¥20.00(1.21%)
Day’s Range― - ―
52-Week Range¥1,142.00 - ¥2,005.00
Previous CloseN/A
Volume203.40K
Average Volume (3M)231.41K
Market Cap
¥66.28B
Enterprise Value¥92.39B
Total Cash (Recent Filing)¥11.57B
Total Debt (Recent Filing)¥36.58B
Price to Earnings (P/E)14.4
Beta0.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.79%
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)1.49
Price to Sales (P/S)1.84
P/FCF Ratio-15.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,400.00Price Target Upside109.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained positive revenue growth indicates growing demand for outsourced R&D services and successful client engagements. Over a multi-month horizon this supports scale benefits, recurring contract pipelines and the ability to reinvest in capacity and specialized capabilities that drive long-term competitive strength.
High Gross MarginsA gross margin consistently above 50% reflects durable cost advantages or pricing power in specialized nonclinical and clinical services. This margin buffer supports reinvestment in facilities and expertise, cushions operating results against revenue swings, and underpins sustainable profitability if maintained.
Business Model / Market PositionThe CRO model provides structurally recurring revenue from pharma/biotech outsourcing, with diversified streams across preclinical, clinical and lab-animal services. Long-term industry secular trends toward outsourcing and regulatory-driven study needs support steady demand and durable client relationships.
Bears Say
Declining Net MarginsEroding net margins reduce retained earnings available for capex, R&D and shareholder returns. If margin decline persists it signals rising overheads, pricing pressure or unfavorable mix, weakening the firm's ability to fund growth internally and increasing sensitivity to cost inflation.
Rising LeverageIncreasing leverage heightens financial risk and interest burden, limiting strategic flexibility to invest or weather downturns. Over a 2-6 month horizon, higher debt constrains capital allocation choices, may raise refinancing risk, and reduces resilience against project timing or client payment variability.
Negative Free Cash FlowPersistent negative free cash flow implies operating profits are not fully converting to spendable cash after investments. This may force reliance on external financing, impede capacity expansion or dividend stability, and increase vulnerability if top-line growth slows or funding conditions tighten.
Shin Nippon Biomedical Laboratories, Ltd. News
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
Shin Nippon Biomedical Laboratories, Ltd. lowest stock price was ¥1142.00 and its highest was ¥2005.00 in the past 12 months.
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
Shin Nippon Biomedical Laboratories, Ltd.’s market cap is ¥66.28B.
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Currently, no data Available
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
According to Wall Street analysts Shin Nippon Biomedical Laboratories, Ltd.’s price is currently Undervalued.
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
Shin Nippon Biomedical Laboratories, Ltd. pays a Semiannually dividend of ¥30 which represents an annual dividend yield of 2.79%. See more information on Shin Nippon Biomedical Laboratories, Ltd. dividends here
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding.
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
Currently, no hedge funds are holding shares in JP:2395
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
2395 Stock 12 Month Forecast
Average Price Target
¥3,400.00
▲(109.62% Upside)
Technical Analysis
Options Prices
Currently, No data available
---